Metraipolis › archive › dc_87d563d985e6

Efficacy, safety, and biomarkers of neoadjuvant trastuzumab and pertuzumab combined with chemotherapy in Chinese patients with HER2-positive breast cancer: a… — Europe PMC PMID:41056055

Source
Europe PMC (en)
Original
https://europepmc.org/article/MED/41056055
DOI
10.1097/js9.0000000000003551
License (as archived)
solo-consultazione
Archived
2026-10-06T08:18:10.820Z
SHA-256 of the archived text
a2cc0219730c58850f14c0b31be5bf562c82a111d9291c05b3f3cfa3fa72096a
Stable URL of this page
https://metraipolis.com/documento/dc_87d563d985e6

How to cite

Efficacy, safety, and biomarkers of neoadjuvant trastuzumab and pertuzumab combined with chemotherapy in Chinese patients with HER2-positive breast cancer: a… — Europe PMC PMID:41056055 — Europe PMC (en), https://europepmc.org/article/MED/41056055 (solo-consultazione); archived copy: https://metraipolis.com/documento/dc_87d563d985e6 (Metraipolis archive dc_87d563d985e6, sha256 a2cc0219730c58850f14c0b31be5bf562c82a111d9291c05b3f3cfa3fa72096a)
BibTeX
@misc{dc87d563d985e6,
  title = {Efficacy, safety, and biomarkers of neoadjuvant trastuzumab and pertuzumab combined with chemotherapy in Chinese patients with HER2-positive breast cancer: a… — Europe PMC PMID:41056055},
  howpublished = {Europe PMC (en)},
  url = {https://europepmc.org/article/MED/41056055},
  note = {License solo-consultazione; archived copy https://metraipolis.com/documento/dc_87d563d985e6; sha256 a2cc0219730c58850f14c0b31be5bf562c82a111d9291c05b3f3cfa3fa72096a},
  year = {2026}
}

Archived text

The text is not reproduced here: the archive holds it as solo-consultazione (consultation only, no republication). Read it at the original source: https://europepmc.org/article/MED/41056055. Agents can read the archived copy with the MCP tool read_document.